Overview

Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2021-01-20
Target enrollment:
Participant gender:
Summary
To monitor the safety profile and effectiveness of Vahelva Respimat in Korean patients with COPD in a routine clinical practice setting
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Olodaterol
Tiotropium Bromide